Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 25 of 147 for:    visilizumab

Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Women With HER2/Neu-Negative Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01022138
Recruitment Status : Unknown
Verified May 2017 by Amy Weise, Barbara Ann Karmanos Cancer Institute.
Recruitment status was:  Active, not recruiting
First Posted : December 1, 2009
Last Update Posted : May 22, 2017
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Amy Weise, Barbara Ann Karmanos Cancer Institute

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : January 2018
Estimated Study Completion Date : January 2018